Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
Hosted on MSN1d
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds StrongShares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...
StockStory.org on MSN7d
Why Merck (MRK) Stock Is Falling TodayShares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...
Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company ...
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback